ENDPOINTS

Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial

GUBamy, the amylin obesity candidate developed by Gubra and licensed to AbbVie for $350 million last month, demonstrated encouraging weight loss in an early trial. The Danish company

Apr 1, 2025 - 16:05
 0
Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial
GUBamy, the amylin obesity candidate developed by Gubra and licensed to AbbVie for $350 million last month, demonstrated encouraging weight loss in an early trial. The Danish company
Read More

Tags:

Previous Article

Compass Therapeutics cancer trial succeeds, needs more data

Next Article

Q&A: Isomorphic Labs CEO Demis Hassabis on $600M raise, AI biotech's future

Related Posts

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly PrEP drug

Gilead plans to skip from Phase 1 to Phase 3 with once-...

Mar 11, 2025  0

At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label

At long last, Novartis’ radiopharma drug Pluvicto gets ...

Mar 28, 2025  0

Curevo gets $110M for a shot against Shingrix, gets Moncef Slaoui and Tal Zaks on board

Curevo gets $110M for a shot against Shingrix, gets Mon...

Mar 17, 2025  0